TY - JOUR T1 - Polygenic associations and causal inferences between serum immunoglobulins and amyotrophic lateral sclerosis JF - medRxiv DO - 10.1101/2020.04.07.20057265 SP - 2020.04.07.20057265 AU - Xu Chen AU - Xiaojun Shen AU - Yiqiang Zhan AU - Fang Fang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/15/2020.04.07.20057265.abstract N2 - Chronic inflammation might contribute to the development of amyotrophic lateral sclerosis (ALS), the relationship between serum immunoglobulins and risk of ALS remains however unclear. In order to overcome limitations like reverse causation and residual confounding commonly seen in the observational studies, we applied molecular epidemiological analyses to examine the polygenic and causal associations between serum immunoglobulins and ALS. Summary statistics from the large-scale genome-wide association studies (GWAS) among European ancestry populations (~15000 individuals for serum immunoglobulins, and more than 36000 individuals for ALS) were accessed from different consortia. The relationships between three types of serum immunoglobulins (IgA, IgM, and IgG) and ALS were investigated in a discovery phase and then in a replication phase. Polygenic risk score (PRS) analysis was performed with PRSice package to test the polygenic association, and Mendelian randomization (MR) analysis was performed with TwoSampleMR package to infer the causality. An inverse polygenic association was discovered between IgA and ALS as well as between IgM and ALS. Such associations were however not replicated using a larger GWAS of ALS, and no causal association was observed for either IgA-ALS or IgM-ALS. A positive polygenic association was both discovered [odds ratio (OR) = 1.18, 95% confidence interval (CI): 1.12-1.25, P=5.9×10’7] and replicated (OR=1.13, 95% CI: 1.06-1.20, P=0.001) between IgG and ALS. A causal association between IgG and ALS was also suggested in both the discovery (OR=1.06, 95%CI: 1.02-1.10, P=0.009) and replication (OR=1.07, 95%CI: 0.90-1.24, P=0.420) analyses, although the latter was not statistically significant. This study suggests a shared polygenic risk between serum IgG (as a biomarker for chronic inflammation) and ALS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is supported by the Science, Technology and Innovation Bureau of Baoan District (Grant No.: 2020JD445), the Swedish Research Council (Grant No.: 2019-01088) and Karolinska Institutet (Senior Researcher Award and Strategic Research Area in Epidemiology).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics of ALS were accessed from the Project MinE group and the ALS Variant Server. http://als.umassmed.edu/ http://databrowser.projectmine.com/ ER -